Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs148609049
rs148609049
0.010 GeneticVariation BEFREE It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95% CI 1.03-2.36). 30157291

2018

dbSNP: rs368234815
rs368234815
0.010 GeneticVariation BEFREE We show that the <i>IFNL4</i> rs368234815-ΔG allele was significantly associated with IRDS in prostate tumors and overall survival of AA patients. 30012562

2018

dbSNP: rs1057519864
rs1057519864
AR
0.010 GeneticVariation BEFREE CDK4/6i was also effective in prostate tumor models expressing the AR-V7 variant or the AR F876L mutation, both of which are associated with treatment resistance. 28209757

2017

dbSNP: rs1060501201
rs1060501201
0.010 GeneticVariation BEFREE Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. 28186998

2017

dbSNP: rs1197734477
rs1197734477
0.010 GeneticVariation BEFREE Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. 28186998

2017

dbSNP: rs2155222
rs2155222
0.010 GeneticVariation BEFREE The findings indicate the functionality of the PrCa death-predisposing SNPs rs143975731, rs12277366, rs2155225, and rs2155222 as DGAT2 regulators in prostate tumors.© 2016 Wiley Periodicals, Inc. 27113481

2016

dbSNP: rs1057519971
rs1057519971
0.010 GeneticVariation BEFREE We sequenced the SPOP gene to identify somatic mutations in 49 AA prostate tumors and identified three missense mutations (p.Y87C, p.F102S, and p.G111E) in five AA prostate tumors (10%) and one synonymous variant (p.I106I) in one tumor. 24994784

2015

dbSNP: rs339331
rs339331
0.010 GeneticVariation BEFREE Finally, we observe a significant association between the risk-associated T allele at rs339331 and increased RFX6 mRNA levels in human prostate tumors. 24390282

2014

dbSNP: rs375118292
rs375118292
0.010 GeneticVariation BEFREE Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion. 24796539

2014

dbSNP: rs727502792
rs727502792
0.010 GeneticVariation BEFREE Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion. 24796539

2014

dbSNP: rs746001963
rs746001963
ERG
0.010 GeneticVariation BEFREE Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion. 24796539

2014

dbSNP: rs1057519912
rs1057519912
0.010 GeneticVariation BEFREE So far, the recently reported MED12 p.L1224F mutation could not be validated in our unselected cohort of prostate tumours. 23661306

2013

dbSNP: rs16861209
rs16861209
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2011

dbSNP: rs17366568
rs17366568
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2011

dbSNP: rs182052
rs182052
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2011

dbSNP: rs266729
rs266729
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2011

dbSNP: rs3774261
rs3774261
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2011

dbSNP: rs7639352
rs7639352
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2011

dbSNP: rs1512268
rs1512268
0.010 GeneticVariation BEFREE Genome-wide association studies (GWAS) identified multiple susceptible loci for prostate cancer (PC), and recent GWAS implicated that a common variant rs1512268 on chromosome 8p21 is associated with PC susceptibility, which is located at 14 kb downstream of a prostate tumor suppressor gene NKX3.1. 20716579

2010

dbSNP: rs113488022
rs113488022
0.010 GeneticVariation BEFREE In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V6</span>00E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency. 19079609

2008

dbSNP: rs121913377
rs121913377
0.010 GeneticVariation BEFREE In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V6</span>00E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency. 19079609

2008

dbSNP: rs976306779
rs976306779
AR
0.010 GeneticVariation BEFREE In our study, we evaluated the functional significance of S100P expression on prostate tumor growth in vitro and in vivo. 18452169

2008

dbSNP: rs1571801
rs1571801
0.010 GeneticVariation BEFREE Analysis of the distribution of these SNPs among 1032 prostate cancer patients and 571 control subjects of European descent indicated that one, rs1571801, located in the DAB2IP gene, which encodes a novel Ras GTPase-activating protein and putative prostate tumor suppressor, was associated with aggressive prostate cancer (one-sided P value = .004). 18073375

2007

dbSNP: rs28909982
rs28909982
0.010 GeneticVariation BEFREE In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo. 16835864

2006

dbSNP: rs587782480
rs587782480
0.010 GeneticVariation BEFREE In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo. 16835864

2006